Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
- Published In:
- Mayo Clinic proceedings, 92(2), 200-210 (2017)
- Authors:
- Cosman, Felicia, Miller, Paul D, Williams, Gregory C, Hattersley, Gary, Hu, Ming-Yi, Valter, Ivo, Fitzpatrick, Lorraine A, Riis, Bente Juel, Christiansen, Claus, Bilezikian, John P, Black, Dennis
- Database ID:
- RPEP-03253
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03253APA
Cosman, Felicia; Miller, Paul D; Williams, Gregory C; Hattersley, Gary; Hu, Ming-Yi; Valter, Ivo; Fitzpatrick, Lorraine A; Riis, Bente Juel; Christiansen, Claus; Bilezikian, John P; Black, Dennis. (2017). Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.. Mayo Clinic proceedings, 92(2), 200-210. https://doi.org/10.1016/j.mayocp.2016.10.009
MLA
Cosman, Felicia, et al. "Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.." Mayo Clinic proceedings, 2017. https://doi.org/10.1016/j.mayocp.2016.10.009
RethinkPeptides
RethinkPeptides Research Database. "Eighteen Months of Treatment With Subcutaneous Abaloparatide..." RPEP-03253. Retrieved from https://rethinkpeptides.com/research/cosman-2017-eighteen-months-of-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.